# Martti Antero Frkkil

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2514777/martti-antero-farkkila-publications-by-year.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

9,077
citations

45
h-index

93
g-index

186
ext. papers

6.4
avg, IF

L-index

#	Paper	IF	Citations
167	Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	1
166	Immunoassay for trypsinogen-4 Analytical Biochemistry, 2022, 114681	3.1	
165	Hospital Volume of Antireflux Surgery in Relation to Endoscopic and Surgical Re-interventions. <i>Annals of Surgery</i> , <b>2021</b> , 274, e1138-e1143	7.8	1
164	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00315	4.2	4
163	Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251392	3.7	O
162	Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. <i>Diagnostic Pathology</i> , <b>2021</b> , 16, 41	3	1
161	Presence of interferon-[4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 849-854	2.4	1
160	Mortality, Reoperation, and Hospital Stay Within 90 Days of Primary and Secondary Antireflux Surgery in a Population-Based Multinational Study. <i>Gastroenterology</i> , <b>2021</b> , 160, 2283-2290	13.3	2
159	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2590-2600	7.9	2
158	Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. <i>Annals of Surgery</i> , <b>2021</b> , 274, e535-e540	7.8	7
157	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1180-1188.e4	6.9	6
156	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 321-329	13.4	17
155	Low serum vitamin D level associated with incident advanced liver disease in the general population - a prospective study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 299-303	2.4	O
154	Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland. <i>BMJ Open</i> , <b>2021</b> , 11, e046667	3	12
153	Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1020-1027	3.3	O
152	Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
151	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , <b>2021</b> , 161, 1764-1775.e5	13.3	O

### (2020-2021)

150	Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , <b>2021</b> ,	5.3	1
149	Biliary hCGIs a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. <i>Livers</i> , <b>2021</b> , 1, 322-329		1
148	Evaluating drug targets through human loss-of-function genetic variation. <i>Nature</i> , <b>2020</b> , 581, 459-464	50.4	53
147	The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> , <b>2020</b> , 581, 434-443	50.4	2278
146	A structural variation reference for medical and population genetics. <i>Nature</i> , <b>2020</b> , 581, 444-451	50.4	223
145	Transcript expression-aware annotation improves rare variant interpretation. <i>Nature</i> , <b>2020</b> , 581, 452-45	5850.4	55
144	Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 347-353	2.4	4
143	Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 462-471	5.3	4
142	Role of Autoimmunity in Patients Transplanted for Acute Liver Failure of Unknown Origin: A Clinical and Graft Biopsy Analysis. <i>Liver Transplantation</i> , <b>2020</b> , 26, 764-773	4.5	2
141	Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 154-162	7.3	14
140	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , <b>2020</b> , 72, 1253-1266	11.2	15
139	Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 74-81	2.4	18
138	Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2020</b> , 44, 384-403	3.7	17
137	REPLY. <i>Hepatology</i> , <b>2020</b> , 71, 1888-1889	11.2	1
136	Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 80-88	7.5	0
135	Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 995-997.e2	6.9	9
134	Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. <i>Hepatology</i> , <b>2020</b> , 71, 835-848	11.2	45
133	Genetic and lifestyle risk factors for advanced liver disease among men and women. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 291-298	4	9

132	Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 984-990	2.4	3
131	LBP-01-In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e141	13.4	2
130	THU-251-Metabolic risk factors for advanced liver disease among alcohol risk users in the general population. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e273	13.4	3
129	Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 707-711	2.4	7
128	A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 648-655	0.7	23
127	Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1294-1299	3.3	21
126	Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 849-854	2.4	9
125	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1704-1705	6	
124	Serum lipopolysaccharides predict advanced liver disease in the general population. <i>JHEP Reports</i> , <b>2019</b> , 1, 345-352	10.3	9
123	Inflammatory bowel disease and anemia: intravenous iron treatment. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 430-434	2.4	5
122	Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. <i>Lipids</i> , <b>2018</b> , 53, 323-334	1.6	0
121	Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 947-951	2.4	6
120	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2018</b> , 155, 752-759.e5	13.3	44
119	Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1576-1582	13.4	12
118	The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. <i>Liver International</i> , <b>2018</b> , 38, 2329-2339	7.9	12
117	Insights into the genetic epidemiology of Crohnß and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007329	6	41
116	Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. <i>Hepatology</i> , <b>2018</b> , 67, 2141-2149	11.2	98
115	Fecal Calprotectin Test Performed at Home: A Prospective Study of Pediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2018</b> , 66, 926-931	2.8	10

### (2017-2018)

114	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , <b>2018</b> , 67, 1517-1524	19.2	28
113	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , <b>2017</b> , 37, 1554-1561	7.9	39
112	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
111	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1214-1222	13.4	34
110	Histologic surveillance after liver transplantation due to autoimmune hepatitis. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12936	3.8	13
109	Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 886-892	2.4	6
108	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1265-1281	13.4	62
107	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , <b>2017</b> , 49, 588-608	3.4	94
106	Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis. <i>Liver International</i> , <b>2017</b> , 37, 735-742	7.9	6
105	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 549-558	13.4	138
104	Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo). BMJ Open, 2017, 7, e016505	3	10
103	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 325-336	18.8	153
102	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 269-273	<sub>3</sub> 36.3	140
101	Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 3123-3130	4	20
100	Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182924	3.7	40
99	Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6147-6154	5.6	5
98	Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy. European Journal of Gastroenterology and Hepatology, <b>2017</b> , 29, 1251-1257	2.2	6
97	Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 321-327	2.4	6

96	Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 242-249	2.4	14
95	Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFII-blocking agents. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 284-290	2.4	12
94	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , <b>2017</b> , 65, 907-919	11.2	50
93	Biliary Anomalies in Patients With HNF1B Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2075-2082	5.6	9
92	Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1190	8.4	30
91	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179764	3.7	21
90	Does oral $\square$ -galactosidase relieve irritable bowel symptoms?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 16-21	2.4	10
89	Outcome of inflammatory bowel disease patients treated with TNF-[] inhibitors: two-year follow-up. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 1476-1481	2.4	7
88	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , <b>2016</b> , 7, 12342	17.4	41
87	Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 825-32	4.6	9
86	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 337-43	2.4	10
85	Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 562-9	5.3	17
84	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 150, 380-8.e4	13.3	85
83	Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. <i>Endoscopy</i> , <b>2016</b> , 48, 432-9	3.4	25
82	Infliximab-induced skin manifestations in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 563-71	2.4	31
81	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155142	3.7	8
80	Environmental Risk Factors of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2016</b> , 62, 437-42	2.8	10
79	Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2616-21	7.5	8

# (2013-2016)

78	Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 961-6	2.4	15
77	A randomized, controlled study of peginterferon lambda-1a/ribavirin daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , <b>2016</b> , 5, 1365		3
76	Helsinki alert of biodiversity and health. <i>Annals of Medicine</i> , <b>2015</b> , 47, 218-25	1.5	79
75	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , <b>2015</b> , 62, 188-97	11.2	76
74	Health-related quality of life among patients with primary sclerosing cholangitis. <i>Liver International</i> , <b>2015</b> , 35, 2194-201	7.9	14
73	Malignancies in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, <b>2015</b> , 50, 81-9	2.4	10
72	Does fecal calprotectin predict short-term relapse after stopping TNFII-blocking agents in inflammatory bowel disease patients in deep remission?. <i>Journal of Crohnmand Colitis</i> , <b>2015</b> , 9, 33-40	1.5	66
71	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. <i>Hepatology</i> , <b>2014</b> , 59, 2131-9	11.2	31
70	Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Journal of Crohnmand Colitis</i> , <b>2014</b> , 8, 1088-96	1.5	45
69	Reply: To PMID 24519039. <i>Hepatology</i> , <b>2014</b> , 60, 2130-1	11.2	
69 68	Reply: To PMID 24519039. <i>Hepatology</i> , <b>2014</b> , 60, 2130-1  A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601	3.7	4
	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver		4 56
68	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601  Outcome after discontinuation of TNFII-blocking therapy in patients with inflammatory bowel	3.7	
68 67	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601  Outcome after discontinuation of TNFII-blocking therapy in patients with inflammatory bowel disease in deep remission. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1021-8  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. <i>International Journal of Cancer</i> ,	3·7 4·5	56
68 67 66	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601  Outcome after discontinuation of TNFII-blocking therapy in patients with inflammatory bowel disease in deep remission. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1021-8  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 189-96  Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal	3·7 4·5 7·5	56 63
68 67 66	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601  Outcome after discontinuation of TNFII-blocking therapy in patients with inflammatory bowel disease in deep remission. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1021-8  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 189-96  Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn® disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 543-51  Medication use among inflammatory bowel disease patients: excessive consumption of	3·7 4·5 7·5	<ul><li>56</li><li>63</li><li>56</li></ul>
68 67 66 65 64	A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601  Outcome after discontinuation of TNFII-blocking therapy in patients with inflammatory bowel disease in deep remission. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1021-8  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 189-96  Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn® disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 543-51  Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 42-50  High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South	3·7 4·5 7·5 2·4	<ul><li>56</li><li>63</li><li>56</li><li>21</li></ul>

60	Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 839-47	2.4	13
59	A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. <i>Endoscopy</i> , <b>2013</b> , 45, 915-9	3.4	28
58	Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 1405-13	2.4	58
57	Dendritic cells from Crohn <b>R</b> disease patients show aberrant STAT1 and STAT3 signaling. <i>PLoS ONE</i> , <b>2013</b> , 8, e70738	3.7	14
56	Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3810-8	5.6	47
55	Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 555-61	4.5	40
54	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1909-15	40	394
53	Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. <i>Liver International</i> , <b>2012</b> , 32, 783-9	7.9	22
52	PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. <i>BMC Medical Genetics</i> , <b>2012</b> , 13, 82	2.1	20
51	A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. <i>Journal of Crohnmand Colitis</i> , <b>2012</b> , 6, 724-7	1.5	15
50	Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF blocking agents. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2011-7	4.5	132
49	In Crohnß Disease, Anti-TNF-🏿 Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. <i>ISRN Gastroenterology</i> , <b>2012</b> , 2012, 505432		10
48	Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn® disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 528-37	2.4	119
47	Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohnß disease detected by wireless capsule endoscopy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 778-84	2.4	68
46	Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. <i>PLoS ONE</i> , <b>2012</b> , 7, e29370	3.7	30
45	Impact of obesity on the bioavailability of peginterferon-□2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. <i>PLoS ONE</i> , <b>2012</b> , 7, e37521	3.7	13
44	Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. <i>Journal of Crohnmand Colitis</i> , <b>2011</b> , 5, 41-7	1.5	64
43	Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. <i>Journal of Crohnmand Colitis</i> , <b>2011</b> , 5, 484-98	1.5	78

# (2009-2011)

42	Patient-controlled sedation with propofol and remifentanil for ERCP: a randomized, controlled study. <i>Gastrointestinal Endoscopy</i> , <b>2011</b> , 73, 260-6	5.2	36
41	Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial. <i>Gastroenterology</i> , <b>2011</b> , 140, S-112	13.3	14
40	Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2011</b> , 35, 516-22	3.7	14
39	Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 1748-52	7	42
38	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , <b>2011</b> , 53, 1067-8	11.2	4
37	Endoscopic monitoring of infliximab therapy in Crohnß disease. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 947-53	4.5	24
36	Capsule endoscopy in pediatric patients: technique and results in our first 100 consecutive children. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 1138-43	2.4	34
35	Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, e22-5	11.6	2
34	Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn® disease treatment. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 325-31	2.4	126
33	Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. <i>Gastroenterology</i> , <b>2010</b> , 139, 1198-206	13.3	278
32	Societal costs for irritable bowel syndromea population based study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 582-91	2.4	43
31	Esophageal morbidity and function in adults with repaired esophageal atresia with tracheoesophageal fistula: a population-based long-term follow-up. <i>Annals of Surgery</i> , <b>2010</b> , 251, 1167-	73 <sup>8</sup>	109
30	Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. <i>Quality of Life Research</i> , <b>2010</b> , 19, 919-28	3.7	23
29	Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 52, 430-5	11.2	69
28	Endoscopic evaluation of Crohn® disease activity: comparison of the CDEIS and the SES-CD. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 2131-6	4.5	89
27	PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1562-9	4.5	44
26	Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. <i>Quality of Life Research</i> , <b>2009</b> , 18, 961-9	3.7	38
25	IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. <i>BMC Medical Genetics</i> , <b>2009</b> , 10, 8	2.1	53

24	Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. <i>Liver International</i> , <b>2009</b> , 29, 153-8	7.9	8
23	Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. <i>Liver International</i> , <b>2008</b> , 28, 787-97	7.9	21
22	Symptoms, endoscopic findings and histology predicting symptomatic benefit of Helicobacter pylori eradication. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 810-6	2.4	4
21	Effect of smoking on gastric histology in Helicobacter pylori-positive gastritis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 1177-83	2.4	20
20	Gastroesophageal reflux patientsRdefective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up. <i>Annals of Medicine</i> , <b>2008</b> , 40, 74-80	1.5	4
19	Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 821-30	2.4	18
18	Nizatidine and gastric emptying in functional dyspepsia. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 352-7	4	13
17	Novel CARD15/NOD2 mutations in Finnish patients with Crohnß disease and their relation to phenotypic variation in vitro and in vivo. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 176-85	4.5	16
16	Crohnß disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohnß disease activity index and endoscopic findings. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 40-6	4.5	338
15	Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1118-24	4.5	57
14	IL-23/IL-17 immunity as a hallmark of Crohn® disease. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1175-84	4.5	156
13	Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnß disease. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1392-8	4.5	178
12	Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , <b>2008</b> , 47, 1837-45	11.2	171
11	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. <i>Hepatology</i> , <b>2008</b> , 48, 695	11.2	11
10	Comorbidity and use of health-care services among irritable bowel syndrome sufferers. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 799-806	2.4	43
9	Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 1347-53	2.4	54
8	Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. <i>Hepatology</i> , <b>2004</b> , 40, 1379-86	11.2	141
7	Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21. <i>European Journal of Human Genetics</i> , <b>2001</b> , 9, 328-34	5.3	37

#### LIST OF PUBLICATIONS

6	Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. <i>European Journal of Haematology</i> , <b>1996</b> , 56, 82-7	3.8	43
5	Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: Cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. <i>Hepatology</i> , <b>1995</b> , 21, 89-95	11.2	18
4	Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. <i>Hepatology</i> , <b>1995</b> , 21, 1261-1268	11.2	18
3	Psychiatric assessment of globus pharyngis patients. <i>Nordic Journal of Psychiatry</i> , <b>1992</b> , 46, 303-306	2.3	0
2	Low prevalence of hepatitis C antibodies in chronic liver disease in Finland. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1991</b> , 23, 139-42		6
1	Lipid metabolism in bile acid malabsorption. <i>Annals of Medicine</i> , <b>1990</b> , 22, 5-13	1.5	24